April 21, 2014 — Decision Resources Group announced in a report that Servier's ivabradine (procoralan) is set to become the clinical gold standard in the treatment of chronic heart failure (CHF). Already available in Europe, where it has enjoyed moderate use in CHF and stable angina patients, ivabradine's clinical profile could prime this agent for a potentially successful launch in the United States, where Amgen own the marketing rights to procoralan.

April 21, 2014 — Cardiologists and cancer experts at the Mount Sinai Hospital in Manhattan have joined forces to establish its first cardio-oncology clinic at the Tisch Cancer Institute.

Providence Saint Joseph Medical Center in Burbank, Calif., is the first hospital in the nation to conduct a magnetic resonance imaging (MRI) scan of a patient implanted with a new MRI-compatible pacemaker — a breakthrough because metal implants often exclude patients from this imaging because of the strong magnetic force.

 

Treatment options for high-risk heart patients with severely calcified coronary artery disease (CAD) have been limited for more than 20 years. Now, Robert Wood Johnson University Hospital (RWJUH) in New Brunswick, N.J., offers a new alternative to open up blocked arteries.

Tendyne Holdings Inc. has secured $25 million in an oversubscribed Series C financing led by Apple Tree Partners, along with Boulle Group members and other existing investors. 

Cytori Stem Cell Therapy Heart Failure Treatments PRECISE Trial

Cytori Therapeutics announced publication of safety and efficacy data from a 36 month European clinical trial of Cytori Cell Therapy in patients with chronic ischemic heart failure. 

April 18, 2014 — New research presented at the 34th annual meeting of the International Society for Heart and Lung Transplantation (ISHLT) demonstrated the CorMatrix particulate extracellular matrix (P-ECM) alone and as an adjunct to HeartWare International Inc.’s left ventricular assist device (LVAD) improved cardiac function in a bovine ischemic heart failure model, as compared to LVAD alone.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now